A few days ago, as Pfizer executives reviewed the pharma giant’s numbers for 2013 and plans for 2014, analysts detected a growing willingness to see if they could hunt up an accelerated approval for palbociclib if the Phase II study for breast cancer rang up promising results.

…read more

Source: Pfizer’s promising results for palbociclib stir talk of early approval push


0 No comments